23价肺炎球菌多糖疫苗和流感疫苗联合接种对慢性阻塞性肺病患者防治的疗效观察

Effectiveness of combine vaccination with 23-valent Pneumococcal Polysaccharide vaccine and Influenza Vaccine to prevent COPD

目的探讨23价肺炎球菌多糖疫苗和流感疫苗联合接种在防治慢性阻塞性肺病患者中的临床意义。方法将64例COPD患者随机分成疫苗组和对照组。疫苗组病人于观察开始前注射肺炎球菌多糖疫苗1次,并于我国流感高发季节前接种灭活流感疫苗。两组患者均观察2年,每2周随访1次。对咳嗽、咳痰、气喘等症状进行临床评价;登记疫苗组2年内急性发作次数、天数、住院次数、平均住院天数、及再发肺部感染的相距时间、与对照组进行对比回顾性分析。结果疫苗组急性发作次数、天数、住院次数、平均住院天数明显低于对照组,而再发肺部感染的相距时间延长。结论23价肺炎球菌疫苗和流感疫苗联合接种能有效减少慢阻肺感染复发率,是临床上防治慢阻肺患者的一个有效方法,值得临床推广。

Objective To investigate clinical significance in the application of 23-valent peneumococcal polysaccharide vaccine and influenza vaccine in COPD patients. Methods 64 cases of COPD patients were randomly divided into experimental group and control group, standardized treatment such as hygienic therapy cough and spasm relieving was given. In the experimental group, besides start standardized treatment, Pneumonia vaccine was injected each year before the epidemic season in China. During the two-year observation, visiting was conducted every two weeks to keep clinic record of coughing, wheezing, times , length of acute outbreak, hospitalization and recurrent interval. Results The times and length of acute outbreak and hospitalization in the experimental group were obviously less than control group, the recurrent interval in the experimental group are longer. Conclusions Multi- Vaccine could effectively reduce recurrent rate of pulmonary infection in COPD patients. Therefore it might be an effective adjuvant for the treatment of COPD, which is worth extending its clinical application.